Allworth Financial LP Sells 1,722 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Allworth Financial LP lessened its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 71.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 680 shares of the company’s stock after selling 1,722 shares during the quarter. Allworth Financial LP’s holdings in CRISPR Therapeutics were worth $32,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of CRSP. Global Trust Asset Management LLC boosted its position in CRISPR Therapeutics by 150.0% during the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares in the last quarter. Larson Financial Group LLC boosted its position in CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after acquiring an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC boosted its position in shares of CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after purchasing an additional 307 shares in the last quarter. Riggs Asset Managment Co. Inc. boosted its position in shares of CRISPR Therapeutics by 66.7% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after purchasing an additional 200 shares in the last quarter. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of CRISPR Therapeutics in the 2nd quarter worth $35,000. Institutional investors own 69.20% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CRSP. Chardan Capital lowered their price objective on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC lowered their price target on CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Royal Bank of Canada lowered their price target on CRISPR Therapeutics from $60.00 to $53.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Finally, Truist Financial lowered their price target on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $75.19.

CRISPR Therapeutics Stock Performance

CRSP stock opened at $50.76 on Friday. The stock has a market capitalization of $4.32 billion, a P/E ratio of -15.18 and a beta of 1.68. CRISPR Therapeutics AG has a one year low of $43.42 and a one year high of $91.10. The company has a 50 day moving average price of $47.11 and a two-hundred day moving average price of $52.44.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The firm had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. The firm’s revenue for the quarter was down 99.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.98) earnings per share. Research analysts forecast that CRISPR Therapeutics AG will post -5.57 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.